Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bo Rueda, Ph.D.


Molecular interrogation of gynecologic tumors:
My group molecularly interrogates gynecologic tumors to identify genes or proteins and their corresponding signaling pathways that contribute to malignant transformation, the pathology of the disease, recurrence and/or resistance to therapy. Once key factors or pathways are identified, we actively test novel anticancer drugs to determine their efficacy in tumor explant models. In addition, we assess the efficacy of dual or sequential therapy. Specifically, we assess whether novel anti-cancer agents work better as a single agent or in conjunction with the standard of care or another anti-cancer agent.

Investigation into the functional significance of the functional contribution of gynecologic cancer stem cells:
My group has extensively studied and continues to conduct research focused on the functional contribution of sub populations of gynecologic cancer cells that have stem like characteristics a contributing to the pathology and high recurrence rate. Our research provided valuable rationale for identifying targetable cells and testing combination therapies that can be tested in clinical trials for women with recurrent and refractory gynecologic cancer.

Define mechanisms that contribute to the genesis, progression or pathology of benign gynecologic diseases:
In addition to in depth studies on gynecologic malignances we also focus on benign diseases that impact reproductive aged women. Specifically, we have and continue to be focused on endometriosis and leiomyoma. These non malignant diseases can have a devastating negative impact on women’s health and quality of life. Despite the prevalence of the disease very little progress have been made in long term solutions with the exception of surgical removal of the of uterus. We have used mouse models as well as primary human tissues to assess the mechanisms by which specific cell signaling factors positively or negatively impact the development, progression and/or pathological properties associated with these diseases. More recently, Dr. Styer and I embarked on an in depth study to assess irregular microRNA (miRNA) expression in leiomyomata compared to matched native myometrium. As a result of these preliminary studies, we have begun in vitro functional studies in primary and immortalized fibroid and myometrial cells. Our ultimate goal is to delineate the functional impact of leiomyoma miRNA expression in the genesis, progression and phenotypic characteristics of the disease. In addition, we anticipate we may uncover novel gene targets that will serve in the development of alternative uterine sparing treatment strategies.

Drug development for treatment of resistant gynecologic cancers:
As a result of our multiple interactions with pharmaceutical companies we have become more proactive in formulating stronger collaborations with the intent to develop novel inhibitors of oncogenic pathways, identify susceptible immune checkpoints, test new immune treatment strategies, and generate specific antibody drug conjugates for the treatment of women diagnosed with endometrial or ovarian cancer.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA176502 (GOLD, LESLIE INA) Jun 13, 2014 - May 31, 2020
    Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
    Role: Co-Principal Investigator
  2. R01CA098333 (RUEDA, BO R) Aug 1, 2003 - May 31, 2009
    Cables role in endometrial differentiation and cancer
    Role: Principal Investigator
  3. R01HD035934 (RUEDA, BO R) Dec 8, 1998 - Jun 30, 2007
    Regulation of the sphingomyelin pathway in the CL
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Rueda's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (629)
Co-Authors (116)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.